MVR-C5252

AXP000081.1 · Oncolytic virus

Platform
HSV-1 (ICP34.5- ICP47-)
Originator
ImmVira Pharma
Sponsor
ImmVira Pharma

Names

NameTypeSource
MVR-C5252preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Replication
conditionally replicating
Modifications
ICP34.5 and ICP47 deleted
Transgenes
IL12A, IL12B, anti-PD-1 antibody
Route
intracerebral
Source
evidence

Cross-references

NCI Thesaurus
C184943

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06126744Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252RecruitingPhase 12024-06-112027-12-0151Recurrent High Grade Glioma
NCT05095441A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive GlioblastomaUnknownPhase 12023-03-152023-04-3051Glioblastoma; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Notes

Glioma-directed oncolytic HSV-1 carrying IL-12 and an anti-PD-1 antibody; delivered into the brain (NCT06126744). Whether it is the same construct as T3011 with a different delivery device, or a distinct construct, is not fully clear from public sources; entered separately because it has its own NCIt concept and code.

How to cite

MVR-C5252 (AXP000081.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000081.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.